Effects of antibodies against human parvovirus B19 on angiogenic signaling

Su,Chia‑Cheng; Hsu,Tsai‑Ching; Hsiao,Chao‑Hsiang; Chiu,Chun‑Ching; Tzang,Bor‑Show

doi:10.3892/mmr.2020.10921

Effects of antibodies against human parvovirus B19 on angiogenic signaling

Authors:
- Chia‑Cheng Su
- Tsai‑Ching Hsu
- Chao‑Hsiang Hsiao
- Chun‑Ching Chiu
- Bor‑Show Tzang
View Affiliations

Affiliations: Department of Urology, Chi Mei Medical Center, Tainan 710, Taiwan, R.O.C., Institute of Biochemistry, Microbiology and Immunology, College of Medicine, Chung Shan Medical University, Taichung 402, Taiwan, R.O.C.
Published online on: January 9, 2020 https://doi.org/10.3892/mmr.2020.10921
Pages: 1320-1327

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human parvovirus B19 (B19V) infection has symptoms similar to those of anti‑phospholipid syndrome (APS). Antibodies against B19V‑VP1 unique region (VP1u) exhibit activity similar to that of anti‑phospholipid antibodies (aPLs) by inducing vascular endothelial cell adhesion factors and APS‑like syndrome. Previous studies have identified an effect of aPLs on angiogenesis. However, little is understood regarding the effect of anti‑B19V‑VP1u antibodies on angiogenesis. The present study investigated the effects of anti‑B19V‑VP1u antibodies on the expression of adhesion molecules and angiogenic signaling using an aPL‑induced human umbilical vein endothelial cell (HUVEC) model, and trypan blue staining and western blotting. The effect of B19V‑VP1u antibodies on vascular endothelial growth factor (VEGF) expression in A549 cells, another well‑known model used to study angiogenesis, was also examined. Significantly higher intracellular adhesion molecule 1 expression was observed following treatments with 10% fetal calf serum (FCS), aPL immunoglobulin G (IgG), B19V‑VP1u IgG or B19V‑NS1 IgG, compared with in the normal human (NH) IgG‑treated cells. Conversely, significantly higher vascular cellular adhesion molecule 1 was only detected in HUVECs treated with B19V‑VP1u IgG. Significantly increased integrin β1 was detected in HUVECs treated with aPL IgG or B19V‑VP1u IgG, whereas no difference in integrin β1 was observed in those treated with 10% FCS, NH IgG or B19V‑NS1 IgG. No difference in AKT‑mTOR‑S6 ribosomal protein (S6RP) signaling was observed in HUVECs treated with B19‑VP1u IgG or B19V‑NS1 IgG, compared with NH IgG‑treated cells. Significantly higher human inducible factor‑1α was detected in HUVECs treated with 10% FCS, aPL IgG, B19V‑VP1u IgG or B19V‑NS1 IgG, compared with in NH IgG‑treated cells. However, there was no difference in the level of VEGF observed among HUVECs treated with NH IgG, B19V‑VP1u IgG or B19V‑NS1 IgG. Notably, no difference in VEGF level was observed in A549 cells treated with NH IgG, aPL IgG, B19V‑VP1u IgG or B19V‑NS1 IgG. These findings suggest that anti‑B19V‑VP1u antibodies may serve a role in activating adhesion molecules, but not in AKT‑mTOR‑S6RP signaling.

View Figures

View References

1	Anderson MJ, Jones SE, Fisher-Hoch SP, Lewis E, Hall SM, Bartlett CL, Cohen BJ, Mortimer PP and Pereira MS: Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet. 1:13781983. View Article : Google Scholar : PubMed/NCBI
2	Reid DM, Reid TM, Brown T, Rennie JA and Eastmond CJ: Human parvovirus-associated arthritis: A clinical and laboratory description. Lancet. 1:422–425. 1985. View Article : Google Scholar : PubMed/NCBI
3	Serjeant GR, Topley JM, Mason K, Serjeant BE, Pattison JR, Jones SE and Mohamed R: Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet. 2:595–597. 1981. View Article : Google Scholar : PubMed/NCBI
4	Brown T, Anand A, Ritchie LD, Clewley JP and Reid TM: Intrauterine parvovirus infection associated with hydrops fetalis. Lancet. 2:1033–1034. 1984. View Article : Google Scholar : PubMed/NCBI
5	Meyer O: Parvovirus B19 and autoimmune diseases. Joint Bone Spine. 70:6–11. 2003. View Article : Google Scholar : PubMed/NCBI
6	Kerr JR: The role of parvovirus B19 in the pathogenesis of autoimmunity and autoimmune disease. J Clin Pathol. 69:279–91. 2016. View Article : Google Scholar : PubMed/NCBI
7	Dorsch S, Liebisch G, Kaufmann B, von Landenberg P, Hoffmann JH, Drobnik W and Modrow S: The VP1 unique region of parvovirus B19V and its constituent phospholipase A2-like activity. J Virol. 76:2014–2018. 2002. View Article : Google Scholar : PubMed/NCBI
8	Tzang BS, Lee YJ, Yang TP, Tsay GJ, Shi JY, Tsai CC and Hsu TC: Induction of antiphospholipid antibodies and antiphospholipid syndrome-like autoimmunity in naive mice with antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta. 382:31–36. 2007. View Article : Google Scholar : PubMed/NCBI
9	Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS and Hsu TC: The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production. Clin Chim Acta. 378:59–65. 2007. View Article : Google Scholar : PubMed/NCBI
10	Lin CY, Chiu CC, Cheng J, Lin CY, Shi YF, Tsai CC, Tzang BS and Hsu TC: Antigenicity analysis of human parvovirus B19-VP1u protein in the induction of anti-phospholipid syndrome. Virulence. 9:208–216. 2018. View Article : Google Scholar : PubMed/NCBI
11	Von Landenberg P, Lehmann HW, Knöll A, Dorsch S and Modrow S: Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Arthritis Rheum. 48:1939–1947. 2003. View Article : Google Scholar : PubMed/NCBI
12	Lunardi C, Tinazzi E, Bason C, Dolcino M, Corrocher R and Puccetti A: Human parvovirus B19 infection and autoimmunity. Autoimmun Rev. 8:116–120. 2008. View Article : Google Scholar : PubMed/NCBI
13	Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, et al: International consensus statement on an update of the classifi cation criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 4:295–306. 2006. View Article : Google Scholar : PubMed/NCBI
14	Linnemann B: Antiphospholipid syndrome - an update. Vasa. 47:451–464. 2018. View Article : Google Scholar : PubMed/NCBI
15	Chen DY, Tzang BS, Chen YM, Lan JL, Tsai CC and Hsu TC: The association of anti-parvovirus B19-VP1 unique region antibodies with antiphospholipid antibodies in patients with antiphospholipid syndrome. Clin Chim Acta. 411:1084–1089. 2010. View Article : Google Scholar : PubMed/NCBI
16	Loizou S, Cazabon JK, Walport MJ, Tait D and So AK: Similarities of specificity and cofactor dependence in serum antiphospholipid antibodies from patients with human parvovirus B19 infection and from those with systemic lupus erythematosus. Arthritis Rheum. 40:103–108. 1997. View Article : Google Scholar : PubMed/NCBI
17	Tzang BS, Tsai CC, Chiu CC, Shi JY and Hsu TC: Up-regulation of adhesion molecule expression and induction of TNF-alpha on vascular endothelial cells by antibody against human parvovirus B19 VP1 unique region protein. Clin Chim Acta. 395:77–83. 2008. View Article : Google Scholar : PubMed/NCBI
18	George J, Blank M, Levy Y, Meroni P, Damianovich M, Tincani A and Shoenfeld Y: Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation. 97:900–906. 1998. View Article : Google Scholar : PubMed/NCBI
19	Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN and Pierangeli SS: Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 52:1545–1554. 2005. View Article : Google Scholar : PubMed/NCBI
20	Di Simone N, Di Nicuolo F, D'Ippolito S, Castellani R, Tersigni C, Caruso A, Meroni P and Marana R: Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod. 83:212–219. 2010. View Article : Google Scholar : PubMed/NCBI
21	Velásquez M, Rojas M, Abrahams VM, Escudero C and Cadavid ÁP: Mechanisms of endothelial dysfunction in antiphospholipid syndrome: Association with clinical manifestations. Front Physiol. 9:18402018. View Article : Google Scholar : PubMed/NCBI
22	Canaud G, Bienaimé F, Tabarin F, Bataillon G, Seilhean D, Noël LH, Dragon-Durey MA, Snanoudj R, Friedlander G, Halbwachs-Mecarelli L, et al: Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 371:303–312. 2014. View Article : Google Scholar : PubMed/NCBI
23	Sakamoto Y, Terashita N, Muraguchi T, Fukusato T and Kubota S: Effects of epigallocatechin-3-gallate (EGCG) on A549 lung cancer tumor growth and angiogenesis. Biosci Biotechnol Biochem. 77:1799–1803. 2013. View Article : Google Scholar : PubMed/NCBI
24	Amann A, Zwierzina M, Koeck S, Gamerith G, Pechriggl E, Huber JM, Lorenz E, Kelm JM, Hilbe W, Zwierzina H and Kern J: Development of a 3D angiogenesis model to study tumour-endothelial cell interactions and the effects of anti-angiogenic drugs. Sci Rep. 7:29632017. View Article : Google Scholar : PubMed/NCBI
25	Tsai CC, Chiu CC, Hsu JD, Hsu HS, Tzang BS and Hsu TC: Human parvovirus B19 NS1 protein aggravates liver injury in NZB/W F1 mice. PLoS One. 8:e5972420132013.
26	Raschi E, Testoni C, Borghi MO, Fineschi S and Meroni PL: Endothelium activation in the anti-phospholipid syndrome. Biomed Pharmacother. 57:282–286. 2003. View Article : Google Scholar : PubMed/NCBI
27	Meroni PL, Raschi E, Testoni C and Borghi MO: Endothelial cell activation by antiphospholipid antibodies. Clin Immunol. 112:169–174. 2004. View Article : Google Scholar : PubMed/NCBI
28	Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, Andrews RK, Rivera J, Iverson GM, Cockerill KA, Linnik MD and Krilis SA: Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX–V. Arthritis Rheum. 54:2558–2567. 2006. View Article : Google Scholar : PubMed/NCBI
29	de Laat B, Derksen RH, van Lummel M, Pennings MT and de Groot PG: Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood. 107:1916–1924. 2006. View Article : Google Scholar : PubMed/NCBI
30	D'Ippolito S, Marana R, Di Nicuolo F, Castellani R, Veglia M, Stinson J, Scambia G and Di Simone N: Effect of low molecular weight heparins (LMWHs) on antiphospholipid antibodies (aPL)-mediated inhibition of endometrial angiogenesis. PLoS One. 7:e296602012. View Article : Google Scholar : PubMed/NCBI
31	Mitsiades CS, Mitsiades N and Koutsilieris M: The Akt pathway: Molecular targets for anti-cancer drug development. Curr Cancer Drug Targets. 4:235–256. 2004. View Article : Google Scholar : PubMed/NCBI
32	Jitschin R, Peters O, Plentz A, Turowski P, Segerer H and Modrow S: Impact of parvovirus B19 infection on paediatric patients with haematological and/or oncological disorders. Clin Microbiol Infect. 17:1336–1342. 2011. View Article : Google Scholar : PubMed/NCBI
33	Yousif L, Hammer GP, Blettner M and Zeeb H: A systematic literature review and meta-analysis. J Med Virol. 85:2165–2175. 2013. View Article : Google Scholar : PubMed/NCBI
34	Ibrahem WN, Hasony HJ and Hassan JG: Human parvovirus B19 in childhood acute lymphoblastic leukaemia in Basrah. J Pak Med Assoc. 64:9–12. 2014.PubMed/NCBI
35	Li Y, Wang J, Zhu G, Zhang X, Zhai H, Zhang W, Wang W and Huang G: Detection of parvovirus B19 nucleic acids and expression of viral VP1/VP2 antigen in human colon carcinoma. Am J Gastroenterol. 102:1489–1498. 2007. View Article : Google Scholar : PubMed/NCBI
36	Wang JH, Zhang WP, Liu HX, Wang D, Li YF, Wang WQ, Wang L, He FR, Wang Z, Yan QG, et al: Detection of human parvovirus B19 in papillary thyroid carcinoma. Br J Cancer. 98:611–618. 2008. View Article : Google Scholar : PubMed/NCBI